Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Immunomedics, Inc.
Information provided by (Responsible Party):
Beth Christian, Ohio State University Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00989586
First received: October 2, 2009
Last updated: September 28, 2014
Last verified: September 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: March 2018
  Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)